Since
2009
Jiangsu Aidea Pharmaceutical Group Co., Ltd. was established in 2009 and listed on the STAR Market of the Shanghai Stock Exchange in 2020 (Stock Code: 688488.SH). The Company is a nationally recognized High-Tech Enterprise and a National-level Specialized, Sophisticated, Distinctive, and Innovative “Little Giant” Enterprise. Focusing on anti-HIV drugs as its core business, while leveraging its competitive advantages in the Human-derived protein field, the Company is actively engaged in the R&D, production, and sales of innovative drugs. It has undertaken 3 projects under the “National New Drug Innovation” Major Project of China and participated in 2 projects under the “Emerging and Major Infectious Disease Prevention and Control” National Science and Technology Major Project. As of mid-2026, the Company has 12 key R&D projects in its pipeline, including six national Class 1 new drugs and six national Class 2 new drugs.
Aidea Pharma is committed to building a comprehensive anti-HIV product portfolio to meet evolving clinical needs. To date, the Company has launched two Class 1 new drugs: Ainuovirine Tablets (Aibangde®), China's first oral anti-HIV Class 1 new drug, and Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (Aitribond®), China's first oral Single Tablet Regimen Class 1 new drug for HIV treatment. Both products have been included in the National Medical Insurance List and the Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS. In 2026, Aidea Pharma achieved significant milestones in its HIV drug portfolio, with the successive approvals of Dolutegravir Sodium Tablets and Darunavir Tablets. These approvals completed the Company's portfolio across three mainstream anti-HIV targets: non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs). The portfolio addresses a broad range of HIV treatment needs, from initial therapy for treatment-naïve patients to treatment options for treatment-experienced patients, including salvage therapy for drug-resistant HIV.
Aidea Pharma focuses on both HIV treatment and prevention, with a R&D pipeline comprising multiple national Class 1 innovative drugs. Among these, ACC017 Tablets, a novel integrase inhibitor, has completed Phase III enrollment, and its core compound patent has been granted in Japan. ADC118 Tablets, a triple fixed-dose combination containing ACC017 as its core component, has completed a bioequivalence (BE) study, with global multicenter clinical development planned. ACC085 Injection, a long-acting HIV capsid inhibitor being developed for pre-exposure prophylaxis (PrEP), has entered Phase I clinical trial.
At the same time, Aidea Pharma continues to strengthen its resource advantages in the human-derived protein sector by actively building an upstream and downstream industrial ecosystem. Through the acquisition of Nanda Pharmaceutical, the Company has established an integrated “human-derived protein API-to-drug product” layout, further reinforcing its dual-driven strategy and creating a second growth curve. In areas such as stroke, two modified new drugs—ADB116 for injection and AD108 injection—Phase I Clinical Trial Initiated, providing strong momentum for the Company's sustainable development.
Looking ahead, Aidea Pharma will continue to uphold its original aspiration for innovation, with sustained investment in the anti-HIV and human-derived protein fields. The Company is committed to delivering higher-quality products and services to society, continuously improving drug accessibility, contributing to the “Healthy China” initiative, and building a Chinese innovative drug brand with global influence.
Note: The project data and development progress presented above are current as of the disclosure date of the 2026 Interim Report.